ZTS Zoetis Inc.
Zoetis Inc. (ZTS) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NYSE. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. On this symbol, 4 comparable calls have settled; 75% reached the published sell target. Information only, not financial advice.
In the buy zone, falling on both timeframes
Price is sitting on the lower trend line — the level that has repeatedly held.
The next few months are read from the last 12 months, not the last 2 years: that channel fits this stock's recent turns at least as well (49% against 46%) and it is the one price is respecting now. The last 2 years stay as context: falling, −31% a year. The nearest ceiling overhead is US$105.91, from the last 2 years. What would overturn this: a close below US$70.27 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 2 years read from
- US$70.26 – US$105.91 Falling channel, −31% a year
- Position in that channel
- 3% 0% at the floor, 100% at the ceiling
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (2 years)
- Lower trend line (2 years)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call today because no target size has paid on this stock’s own record, so there is none to publish. No alerts are sent. The buy and target below are still this site's read of the fitted channel.
Buy at or below
US$70.25
level as at 19 Sept 2026
Our target
US$97.12
by 18 Dec 2026
Projected move
38.3%
gross, before costs
Price sits between our buy level and our target.
On this stock's own history these rules produced 4 settled calls, of which 3 reached target (75%), with an average best move of 7.6%. See the full record.
- Upper line touches
- 8
- Lower line touches
- 3
- Fit confidence
- 46%
- Fitted
- 18 Sept 2026
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kristin C. Peck
- Employees
- 14,500
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$30.56B
- Enterprise value
- —
- Beta
- 0.73
- Avg volume
- 7.09M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 71-152
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.